Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 15/20 | 0.54 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20697242 | 0.87 | IDH1 (0.58) | IDH1TYK2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL20688041 | 0.80 | IDH1 (0.50) | IDH1TYK2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL22421824 | 0.77 | IDH1 (0.46) | IDH1TYK2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL20889875 | 0.76 | IDH1 (0.44) | IDH1TYK2 | |
| SCHEMBL20890070 | 0.75 | IDH1 (0.48) | IDH1TYK2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL20909898 | 0.73 | RECQL (0.50) | IDH1TYK2 | |
| SCHEMBL20689588 | 0.71 | TYK2 (0.45) | IDH1TYK2 | |
| SCHEMBL31262446 | 0.71 | TYK2 (0.45) | IDH1TYK2 | |
| SCHEMBL17603736 | 0.71 | IDH1 (1.00) | IDH1 | |
| SCHEMBL17603739 | 0.71 | IDH1 (1.00) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | IDH1 2497/4885TYK2 1/4885PIK3CD 961/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | IDH1 2497/4885TYK2 1/4885PIK3CD 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.